Dr. Shelley M. Payne, LCID Director, was among three experts recently interviewed by Healthline.com about studies looking at COVID-19 breakthrough infection risk with the Omicron variant. She said that while studies on neutralizing antibodies against the variant are useful, scientists will also need to look at real-world data on

LCID Member Dr. Andrew Ellington spoke recently with Austin news station KXAN on concerns about the Omicron variant of the COVID-19 virus. He addressed how the mutation might affect how easily the virus spreads, but stressed that vaccination is still the greatest weapon against serious disease and further

LCID Researcher Dr. Maria Croyle and her team have developed a vaccine preparation technique that both imparts temperature stability and allows easy administration.

To overcome the issue of temperature sensitivity, some vaccines are freeze-dried, a process known as lyophilization, and transported as powders. But, says Maria Croyle, a pharmacologist at the University of Texas at Austin, in some instances the stability of lyophilized vaccines is less than ideal. For instance, some can be

Dr. Shelley Payne, director of the LaMontagne Center for Infectious Disease at the University of Texas at Austin, said that by the article’s own admission, an unusual characteristic of COVID-19 is that many carriers are asymptomatic.

“Without very large-scale testing, we don’t know who is infected and who is not,” she said via email.